BeiGene Ltd. Total Assets
BeiGene Ltd. total assets. Based on the latest financial reports, BeiGene Ltd. (49B) holds total assets worth €5.84 Billion EUR (≈ $6.83 Billion USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 49B cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of BeiGene Ltd. (2016–2024)
Total assets of BeiGene Ltd. from 2016 to 2024. This chart illustrates how BeiGene Ltd.'s total assets have evolved over time, based on quarterly financial data. See BeiGene Ltd. (49B) share price today for real-time trading data and today's change.
BeiGene Ltd. - Asset Composition Analysis
BeiGene Ltd. Total Assets Breakdown (December 2024)
BeiGene Ltd. total assets breakdown as of December 2024. BeiGene Ltd.'s total assets of €5.84 Billion consist of 67.4% current assets and 32.6% non-current assets. Explore BeiGene Ltd. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.4% |
| Accounts Receivable | €676.28 Million | 11.4% |
| Inventory | €494.99 Million | 8.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €129.76 Million | 2.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BeiGene Ltd.'s current assets represent 67.4% of total assets in 2024, a decrease from 92.3% in 2016.
- Cash Position: Cash and equivalents constituted 44.4% of total assets in 2024, up from 21.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.4% of total assets.
BeiGene Ltd. Competitors by Total Assets
Key competitors of BeiGene Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
BeiGene Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 2.08 | 6.15 |
| Quick Ratio | 1.71 | 1.84 | 6.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.91 Billion | €2.03 Billion | €2.84 Billion |
BeiGene Ltd. - Advanced Valuation Insights
This section examines the relationship between BeiGene Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.05 |
| Latest Market Cap to Assets Ratio | 4.35 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | €5.92 Billion |
| Market Capitalization | $25.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BeiGene Ltd.'s assets at a significant premium (4.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BeiGene Ltd.'s assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BeiGene Ltd. (2016–2024)
The table below shows the annual total assets of BeiGene Ltd. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €5.92 Billion ≈ $6.92 Billion |
+1.99% |
| 2023-12-31 | €5.81 Billion ≈ $6.79 Billion |
-9.00% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
-26.22% |
| 2021-12-31 | €8.65 Billion ≈ $10.11 Billion |
+54.37% |
| 2020-12-31 | €5.60 Billion ≈ $6.55 Billion |
+247.38% |
| 2019-12-31 | €1.61 Billion ≈ $1.88 Billion |
-28.33% |
| 2018-12-31 | €2.25 Billion ≈ $2.63 Billion |
+114.98% |
| 2017-12-31 | €1.05 Billion ≈ $1.22 Billion |
+157.87% |
| 2016-12-31 | €405.81 Million ≈ $474.44 Million |
-- |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more